Philippe Gaulard

Active 1986–2024

187
Papers
37,658
Citations
107
h-index
186
i10-index

Citations

Citations per year for Philippe Gaulard1988: 2 citations1989: 5 citations1990: 6 citations1991: 7 citations1992: 4 citations1993: 10 citations1994: 11 citations1995: 26 citations1996: 28 citations1997: 60 citations1998: 55 citations1999: 45 citations2000: 72 citations2001: 100 citations2002: 115 citations2003: 197 citations2004: 150 citations2005: 197 citations2006: 205 citations2007: 230 citations2008: 279 citations2009: 222 citations2010: 238 citations2011: 275 citations2012: 270 citations2013: 240 citations2014: 263 citations2015: 256 citations2016: 238 citations2017: 275 citations2018: 189 citations2019: 843 citations2020: 821 citations2021: 812 citations2022: 726 citations2023: 553 citations2024: 926 citations2025: 348 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,509 citing papers, 24.1% of this breakdownFrance: 857 citing papers, 8.2% of this breakdownGermany: 731 citing papers, 7% of this breakdownChina: 679 citing papers, 6.5% of this breakdownItaly: 647 citing papers, 6.2% of this breakdownUnited Kingdom: 614 citing papers, 5.9% of this breakdownCanada: 419 citing papers, 4% of this breakdownSpain: 385 citing papers, 3.7% of this breakdownJapan: 367 citing papers, 3.5% of this breakdownSwitzerland: 344 citing papers, 3.3% of this breakdownNetherlands: 303 citing papers, 2.9% of this breakdownAustralia: 219 citing papers, 2.1% of this breakdown
0%24.1%Other 22.6%

Fields

  • Medicine78.1%
  • Biochemistry, Genetics and Molecular Biology11.4%
  • Immunology and Microbiology8.2%
  • Neuroscience1.3%
  • Computer Science0.3%
  • Pharmacology, Toxicology and Pharmaceutics0.1%
  • Other0.6%

Topics

  • Lymphoma Diagnosis and Treatment19.6%
  • Viral-associated cancers and disorders6.3%
  • Chronic Lymphocytic Leukemia Research5.3%
  • CAR-T cell therapy research5%
  • Immune Cell Function and Interaction4.9%
  • CNS Lymphoma Diagnosis and Treatment4.7%
  • Other54.2%

Coauthors

All papers

Open in search
  1. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2002 cited by 5,562

  3. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 192

  4. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurence de Leval, Joseph M. Connors, Jamés O. Armitage, Julie M. Vose, Wing C. Chan, Louis M. Staudt - Blood 2014 cited by 540

  5. Genomic profiling for clinical decision making in lymphoid neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfgang Hiddemann, Won Seog Kim, Rebecca L. King, Young Hyeh Ko, Ann S. LaCasce, Georg Lenz, José I. Martín‐Subero, Miguel Á. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla‐Martínez, Scott J. Rodig, Andreas Rosenwald, Gilles Salles, Jesús F. San Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier Luigi Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott - Blood 2022 cited by 161

  6. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Masao Seto, Andreas Rosenwald, German Ott, Elı́as Campo, Lisa M. Rimsza, Elaine S. Jaffe, Rita M. Braziel, Francesco d’Amore, Giorgio Inghirami, Francesco Bertoni, Laurence de Leval, Philippe Gaulard, Louis M. Staudt, Timothy W. McKeithan, Stefano Pileri, Wing C. Chan, Javeed Iqbal - Blood 2019 cited by 275

  7. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2005 cited by 1,499

  8. Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gaulard, Gilles Salles, Catherine Burton, Daphne de Jong, Laurie H. Sehn, Delphine Maucort‐Boulch - Journal of Clinical Oncology 2019 cited by 254

  9. Human IL4I1 is a secreted l-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation

    Authors: , , , , , , , , , , - Blood 2007 cited by 204

  10. High total metabolic tumor volume at baseline predicts survival independent of response to therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 185

  11. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2011 cited by 545

  12. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

    Authors: , , , , , , , , , , , , , , , - Haematologica 2013 cited by 171

  13. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

    Authors: , , , , , , , , , , , , , - Blood 2012 cited by 500

  14. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

    Authors: , , , , , , , , , , , , , , - Blood 2012 cited by 492

  15. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

    Authors: , , , , , , , , , , , , , - Blood 2007 cited by 621

  16. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin

    Authors: , , , , , , , , , , , , , , , , , , , , - Haematologica 2017 cited by 224

  17. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

    Authors: , , , , , , , , , , , , , - Blood 2018 cited by 178

  18. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 cited by 390

  19. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 318

  20. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Françoise Berger, Céline Bossard, Flavie Arbion, Isabelle Quintin‐Roué, Jean‐Michel Picquenot, Martine Patey, Blandine Fabre, Henri Sevestre, Cécile Le Naourès, Marie-Pierre Chenard-Neu, Claire Bastien, S. Thiebault, Laurent Martin, Manuela Delage, Thomas Filleron, Gilles Salles, Thierry Jo Molina, Georges Delsol, Pierre Brousset, Philippe Gaulard - Journal of Clinical Oncology 2017 cited by 217

  21. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 195

  22. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 57

  23. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yoshiki Akatsuka, Satoru Miyano, Tadashi Yoshino, Philippe Gaulard, Olivier Hermine, Kengo Takeuchi, Koichi Ohshima, Seishi Ogawa - Leukemia 2019 cited by 148

  24. Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Leukemia 2017 cited by 128